Drs. Shapiro and Guerriero Publish Key Findings on the Role of PARP Inhibitors in TNBC

This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8⁺ T-cell recruitment and antitumor efficacy. The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer.

Source: Cancer Discovery